Multi-Osp for comprehensive defense

    Duramune Lyme is a two-strain, whole-cell, multi-Osp vaccine that induces a broad antibody response to many outer surface proteins3 , giving dogs continuous, uninterrupted protection against Lyme disease with annual vaccination4.

    Real-World Safety

    Low incidence of vaccine-associated adverse events (VAAEs) demonstrated in the largest retrospective study ever on canine vaccines.
    • Study is unprecedented in its scope
    • Involved 30,000 doses of Lyme vaccine administered to dogs in real-world clinical settings

    Safe in Lyme-Positive Dogs
    Found to be safe even in dogs seropositive for Borrelia burgdorferi at the time of vaccination and in dogs with a history of Lyme disease

    PureFil Technology
    Manufactured using PureFil technology to reduce extraneous proteins and cellular debris.

    To be safe, a vaccine must be effective. An unprotected patient is a real-life safety concern. Extensive laboratory and field studies demonstrate the ability of DURAMUNE LYME to help keep patients safe from disease.

    Efficacy

    When used annually in any protocol, DURAMUNE LYME helps veterinarians provide routine high-quality patient care and supports the human-animal bond by helping dogs stay Lyme disease-free for life.

    EFFECTIVE ON CHALLENGE
    • 100 percent preventable fraction against clinical disease in a challenge study conducted recently for USDA requalification.
    EFFECTIVE IN REAL PATIENTS
    • Proven 92 percent effective in preventing Lyme disease
    NEUTRALIZES MANY STRAINS
    • Dogs vaccinated with DURAMUNE LYME produced borreliacidal antibodies able to neutralize multiple isolates of the bacteria1
    MULTIPLE OPPORTUNITIES TO PROTECT
    • Multiple outer surface proteins (Osps) provide redundant safeguards for a cascade of protection against Lyme disease
    ANNUAL REVACCINATION
    • Labeled for revaccination in annual protocols to support routine patient care
    *Initial vaccination series with DURAMUNE LYME should be administered to puppies. Dogs should then receive required annual boosters.

    Available in Great Combinations

    Count on the expertise of our highly knowledgeable and experienced sales and support teams. For assistance or to learn more about Lyme disease and our complete line of safe, effective canine vaccines:
    • Talk to your BIVI or distributor representative
    • Call Technical Services, 1-866-638-2226, available 24 hours a day, seven days a week
    1Chu HJ, Chaves LG, Blumer BM, et al. Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. JAVMA. 1992;201(3):403-411.
    2Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. JAVMA. 2005;38(7):1102-1108.
    3LevySA, Lissman BA, Ficke CM. Performance of a Borrelia burgdorferi bacterin in borreliosis-endemic areas. JAVMA 1993;202(11):1834-1838.
    4Data on file. Boehringer Ingelheim Vetmedica, Inc.
    5USDA Requalification Study, 2007.
    6Levy S. Use of a C4 ELISA test to evaluate the efficacy of a whole-cell baterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection. Vet Ther. 2002;3(4):420-424.
    Back to top